CIPO’s Position Statement on Private Insurance and Blood Products
by Lauren
Posted on June 20, 2018
Canadian Immunodeficiencies Patient Organization position statement on private insurance and blood products In April, CSL Behring listed the subcutaneous immune globulin product, Hizentra, with private payers for reimbursement. As of today, it has been approved on some open plan formularies. At this time, CIPO is unable to support the listing of plasma protein products with…